Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuances
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBIAT (2016 - 2025)

Historic EBIAT for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to -$1.1 million.

  • Lifecore Biomedical, Inc. \De\'s EBIAT rose 8380.63% to -$1.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$38.7 million, marking a year-over-year decrease of 48028.68%. This contributed to the annual value of -$38.7 million for FY2025, which is 42229.25% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its EBIAT stood at -$1.1 million for Q2 2025, which was up 8380.63% from -$14.8 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s EBIAT peaked at $15.6 million during Q1 2024, and registered a low of -$38.5 million during Q4 2021.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s EBIAT had a median value of -$10.2 million in 2021 and averaged -$11.0 million.
  • Examining YoY changes over the last 5 years, Lifecore Biomedical, Inc. \De\'s EBIAT showed a top increase of 21121.35% in 2023 and a maximum decrease of 91922.87% in 2023.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s EBIAT stood at -$38.5 million in 2021, then soared by 66.71% to -$12.8 million in 2022, then soared by 211.21% to $14.2 million in 2023, then crashed by 146.14% to -$6.6 million in 2024, then surged by 82.54% to -$1.1 million in 2025.
  • Its EBIAT stands at -$1.1 million for Q2 2025, versus -$14.8 million for Q1 2025 and -$6.6 million for Q4 2024.